◆ FUNDING DATA
- Round
- seed
- Founded
- 2016
- Location
- Parkville, United States
- Priority score
- 50/100
- Confidence
- 45/100
Bond Biosciences develops first-in-class non-absorbed oral therapeutics that bind excess metal ions in the gastrointestinal tract to treat ion-related diseases, with lead candidate BBI-001 designed to treat hereditary hemochromatosis by inhibiting dietary iron absorption.